Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of A SRC Kinase Inhibitor, Dasatinib,in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Recurrent Ovarian, Peritoneal, and Tubal Cancer

NCT00672295 is registered in ClinicalTrials.gov with AA Secord as lead sponsor.

NCT NCT00672295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00672295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of A SRC Kinase Inhibitor, Dasatinib,in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Recurrent Ovarian, Peritoneal, and Tubal Cancer
Lead sponsor
AA Secord
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2007
Completion date
November 30, 2012
Enrollment
11 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian cancer, peritoneal cancer